Prevalence and Prognostic Value of Cachexia Diagnosed by New Definition for Asian People in Older Patients With Heart Failure
Journal of Cachexia, Sarcopenia and Muscle · 2024
DOI: 10.1002/jcsm.13610 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Cachexia, Sarcopenia and Muscle, 2024. Verfasst von Takumi Noda und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rehabilitation Sciences, Kitasato University Graduate School of Medical Sciences, Sagamihara, Japan. Hauptthemen laut MEDLINE: Cachexia, Heart Failure, Asian People. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novartis Pharma, Japan Heart Foundation Research, EN Otsuka Pharmaceutical Co. Ltd..
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Background
The Asian Working Group for Cachexia (AWGC) proposed a new definition of cachexia; however, its impact on cachexia prevalence and overlaps with other conditions, such as sarcopenia and malnutrition, are unclear. We investigated these aspects and the prognostic value of cachexia based on the AWGC on mortality in older patients with heart failure (HF).
Methods
This study was a secondary analysis of a prospective multicentre cohort, namely, the FRAGILE‐HF cohort study. Older (≥ 65 years) patients who had been hospitalized due to decompensated HF were enrolled. We assessed the presence/absence of cachexia based on the AWGC and Evans' criteria. Sarcopenia and malnutrition based on the Asian Working Group for Sarcopenia 2014 and the Global Leadership Initiative on Malnutrition criteria were also assessed to compare their prevalence and the overlaps between them. Patients were stratified in relation to the presence/absence of cachexia based on the AWGC criteria, and their mortality rates were compared.
Results
Of the 861 enrolled patients (median [interquartile range] age, 80 years [73–85 years]; male, 58.9%), cachexia, as evaluated based on the AWGC and Evans' criteria, sarcopenia and malnutrition, was present in 74.1%, 36.2%, 20.6% and 55.2% of patients, respectively. AWGC‐defined cachexia was most common in the four conditions. All‐cause death events occurred in 153 (18.1%) patients in 2 years. AWGC‐defined cachexia (adjusted hazard ratio [aHRs], 1.442; 95% confidence interval [95% CI], 0.931–2.233; p = 0.101) was not associated with all‐cause mortality in older patients with HF after adjusting for other HF prognosis factors, such as the B‐type natriuretic peptide and the Meta‐Analysis Global Group in Chronic risk score, whereas cachexia evaluated based on Evans's criteria (aHRs, 1.547; 95% CI, 1.118–2.141; p = 0.009), sarcopenia (aHRs, 1.737; 95% CI, 1.214–2.485; p = 0.003), and malnutrition (aHRs, 1.581; 95% CI, 1.094–2.284; p = 0.015) was associated with all‐cause mortality.
Conclusions
Three‐quarters of older patients with HF had cachexia as evaluated by the AWGC criteria, and this was not associated with a worse prognosis. As the new AWGC cachexia criteria will result in a significantly larger proportion of patients being diagnosed with cachexia, the implementation of the criteria in clinical practice requires further consideration. Trial Registration: UMIN‐CTR unique identifier: UMIN000023929
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Rehabilitation Sciences, Kitasato University Graduate School of Medical Sciences, Sagamihara, Japan.
- Department of Cardiovascular Rehabilitation, National Cerebral and Cardiovascular Center, Suita, Japan.
- Department of Cardiovascular Medicine, Kitasato University School of Medicine, Sagamihara, Japan.
- Department of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.
- Department of Rehabilitation, School of Allied Health Sciences, Kitasato University, Sagamihara, Japan.
- Division of Research, ARCE Inc., Sagamihara, Japan.
ORCID-Profile: Takumi Noda, Kentaro Kamiya
Förderung
- Novartis Pharma
- Japan Heart Foundation Research
- EN Otsuka Pharmaceutical Co. Ltd.
- Japan Society for the Promotion of Science
Zitieren
APA
Noda, T., Maekawa, E., Maeda, D., Uchida, S., Yamashita, M., Hamazaki, N., Nozaki, K., Saito, H., Saito, K., Ogasahara, Y., Konishi, M., Kitai, T., Iwata, K., Jujo, K., Wada, H., Kasai, T., Nagamatsu, H., Ozawa, T., Izawa, K., …, & Kamiya, K. (2024). Prevalence and Prognostic Value of Cachexia Diagnosed by New Definition for Asian People in Older Patients With Heart Failure. Journal of Cachexia, Sarcopenia and Muscle. https://doi.org/10.1002/jcsm.13610
Vancouver
Noda T, Maekawa E, Maeda D, Uchida S, Yamashita M, Hamazaki N, et al. Prevalence and Prognostic Value of Cachexia Diagnosed by New Definition for Asian People in Older Patients With Heart Failure. Journal of Cachexia, Sarcopenia and Muscle. 2024. doi:10.1002/jcsm.13610
BibTeX
@article{Noda2024,
author = {Noda, Takumi and Maekawa, Emi and Maeda, Daichi and Uchida, Shota and Yamashita, Masashi and Hamazaki, Nobuaki and Nozaki, Kohei and Saito, Hiroshi and Saito, Kazuya and Ogasahara, Yuki and Konishi, Masaaki and Kitai, Takeshi and Iwata, Kentaro and Jujo, Kentaro and Wada, Hiroshi and Kasai, Takatoshi and Nagamatsu, Hirofumi and Ozawa, Tetsuya and Izawa, Katsuya and Yamamoto, Shuhei and Aizawa, Naoki and Yonezawa, Ryusuke and Oka, Kazuhiro and Ako, Junya and Momomura, Shin-Ichi and Kagiyama, Nobuyuki and Matsue, Yuya and Kamiya, Kentaro},
title = {Prevalence and Prognostic Value of Cachexia Diagnosed by New Definition for Asian People in Older Patients With Heart Failure},
journal = {Journal of Cachexia, Sarcopenia and Muscle},
year = {2024},
doi = {10.1002/jcsm.13610}
}
EUVIMED